Which has better valuation & earnings, BCYC or COAG?

Hemab Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bicycle Therapeutics $72.86M 3.88 -$218.96M -$3.15 N/A Hemab Therapeutics N/A N/A N/A N/A N/A

Bicycle Therapeutics (BCYC) Competitors

$4.05 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$4.04 -0.01 (-0.22%)

As of 06/12/2026 07:55 PM Eastern

Compare

BCYC vs. COAG, WVE, MPLT, PAHC, and MRVI

Should you buy Bicycle Therapeutics stock or one of its competitors? MarketBeat compares Bicycle Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bicycle Therapeutics include Hemab Therapeutics (COAG), WAVE Life Sciences (WVE), Maplight Therapeutics (MPLT), Phibro Animal Health (PAHC), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does Bicycle Therapeutics compare to Hemab Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. 8.5% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Hemab Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Hemab Therapeutics' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Hemab Therapeutics	N/A	N/A	N/A

Hemab Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.88	-$218.96M	-$3.15	N/A
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Hemab Therapeutics had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 2 mentions for Hemab Therapeutics and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat Hemab Therapeutics' score of 0.93 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Very Positive
Hemab Therapeutics	Positive

Bicycle Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 245.68%. Hemab Therapeutics has a consensus price target of $41.75, suggesting a potential upside of 67.13%. Given Bicycle Therapeutics' higher possible upside, equities analysts clearly believe Bicycle Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Bicycle Therapeutics beats Hemab Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Bicycle Therapeutics compare to WAVE Life Sciences?

Bicycle Therapeutics (NASDAQ:BCYC) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

In the previous week, WAVE Life Sciences had 6 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 7 mentions for WAVE Life Sciences and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat WAVE Life Sciences' score of 0.88 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Very Positive
WAVE Life Sciences	Positive

WAVE Life Sciences has lower revenue, but higher earnings than Bicycle Therapeutics. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.88	-$218.96M	-$3.15	N/A
WAVE Life Sciences	$42.73M	26.43	-$204.38M	-$1.06	N/A

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bicycle Therapeutics presently has a consensus target price of $14.00, suggesting a potential upside of 245.68%. WAVE Life Sciences has a consensus target price of $26.41, suggesting a potential upside of 349.94%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

WAVE Life Sciences has a net margin of -255.70% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Bicycle Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, suggesting that its stock price is 233% less volatile than the broader market.

Summary

WAVE Life Sciences beats Bicycle Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Maplight Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Maplight Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Maplight Therapeutics' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Maplight Therapeutics	N/A	N/A	N/A

In the previous week, Maplight Therapeutics had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 2 mentions for Maplight Therapeutics and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat Maplight Therapeutics' score of 0.93 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Very Positive
Maplight Therapeutics	Positive

Maplight Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.88	-$218.96M	-$3.15	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

86.2% of Bicycle Therapeutics shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bicycle Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 245.68%. Maplight Therapeutics has a consensus price target of $37.78, suggesting a potential upside of 36.14%. Given Bicycle Therapeutics' higher probable upside, equities research analysts plainly believe Bicycle Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Maplight Therapeutics beats Bicycle Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Phibro Animal Health?

Bicycle Therapeutics (NASDAQ:BCYC) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Phibro Animal Health has a net margin of 6.35% compared to Bicycle Therapeutics' net margin of -344.95%. Phibro Animal Health's return on equity of 37.14% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Phibro Animal Health	6.35%	37.14%	8.57%

Bicycle Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

Bicycle Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 245.68%. Phibro Animal Health has a consensus price target of $38.80, suggesting a potential upside of 23.06%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Bicycle Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Phibro Animal Health had 15 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 16 mentions for Phibro Animal Health and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat Phibro Animal Health's score of 0.77 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Very Positive
Phibro Animal Health	Positive

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 8.5% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Phibro Animal Health has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.88	-$218.96M	-$3.15	N/A
Phibro Animal Health	$1.30B	0.99	$48.26M	$2.33	13.53

Summary

Phibro Animal Health beats Bicycle Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Maravai LifeSciences had 2 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Maravai LifeSciences and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat Maravai LifeSciences' score of 0.64 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Maravai LifeSciences	Positive
Bicycle Therapeutics	Very Positive

Maravai LifeSciences has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Maravai LifeSciences has higher revenue and earnings than Bicycle Therapeutics. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	6.92	-$130.77M	-$0.71	N/A
Bicycle Therapeutics	$72.86M	3.88	-$218.96M	-$3.15	N/A

Maravai LifeSciences presently has a consensus target price of $5.50, suggesting a potential upside of 10.44%. Bicycle Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 245.68%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Maravai LifeSciences has a net margin of -51.07% compared to Bicycle Therapeutics' net margin of -344.95%. Maravai LifeSciences' return on equity of -17.87% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

Summary

Maravai LifeSciences and Bicycle Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Bicycle Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCYC vs. The Competition

Export

Metric	Bicycle Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$282.73M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-1.29	20.00	24.00	24.42
Price / Sales	3.88	306.82	514.36	111.24
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.46	8.32	10.54	6.82
Net Income	-$218.96M	$23.94M	$3.57B	$337.56M
7 Day Performance	-1.46%	1.84%	0.60%	1.17%
1 Month Performance	-8.99%	-0.04%	1.56%	3.16%
1 Year Performance	-51.61%	44.82%	25.42%	30.58%

Bicycle Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCYC Bicycle Therapeutics	3.746 of 5 stars	$4.05 flat	$14.00 +245.7%	-51.6%	$282.73M	$72.86M	N/A	240	Positive News High Trading Volume
COAG Hemab Therapeutics	4.5776 of 5 stars	$27.13 -4.8%	$41.75 +53.9%	N/A	$1.27B	N/A	N/A	72	Quiet Period Expiration Gap Up
WVE WAVE Life Sciences	3.1204 of 5 stars	$6.26 -4.9%	$27.25 +335.3%	-15.5%	$1.27B	$71.80M	N/A	240
MPLT Maplight Therapeutics	3.5019 of 5 stars	$29.76 +1.5%	$37.78 +26.9%	N/A	$1.25B	N/A	N/A	109
PAHC Phibro Animal Health	4.8958 of 5 stars	$29.87 -3.0%	$38.80 +29.9%	+31.8%	$1.25B	$1.50B	12.82	2,475	Trending News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCYC) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. COAG, WVE, MPLT, PAHC, and MRVI

How does Bicycle Therapeutics compare to Hemab Therapeutics?

Summary

How does Bicycle Therapeutics compare to WAVE Life Sciences?

Summary

How does Bicycle Therapeutics compare to Maplight Therapeutics?

Summary

How does Bicycle Therapeutics compare to Phibro Animal Health?

Summary

How does Bicycle Therapeutics compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. COAG, WVE, MPLT, PAHC, and MRVI

How does Bicycle Therapeutics compare to Hemab Therapeutics?

Do insiders and institutionals have more ownership in BCYC or COAG?

Is BCYC or COAG more profitable?

Which has better valuation & earnings, BCYC or COAG?

Does the media prefer BCYC or COAG?

Do analysts recommend BCYC or COAG?

Summary

How does Bicycle Therapeutics compare to WAVE Life Sciences?

Does the media favor BCYC or WVE?

Which has higher valuation and earnings, BCYC or WVE?

Do insiders & institutionals have more ownership in BCYC or WVE?

Do analysts rate BCYC or WVE?

Is BCYC or WVE more profitable?

Which has more risk and volatility, BCYC or WVE?

Summary

How does Bicycle Therapeutics compare to Maplight Therapeutics?

Is BCYC or MPLT more profitable?

Does the media refer more to BCYC or MPLT?

Which has preferable valuation & earnings, BCYC or MPLT?

Do insiders and institutionals have more ownership in BCYC or MPLT?

Do analysts rate BCYC or MPLT?

Summary

How does Bicycle Therapeutics compare to Phibro Animal Health?

Is BCYC or PAHC more profitable?

Which has more volatility and risk, BCYC or PAHC?

Do analysts prefer BCYC or PAHC?

Does the media favor BCYC or PAHC?

Do institutionals & insiders have more ownership in BCYC or PAHC?

Which has preferable valuation and earnings, BCYC or PAHC?

Summary

How does Bicycle Therapeutics compare to Maravai LifeSciences?

Does the media refer more to MRVI or BCYC?

Which has more risk and volatility, MRVI or BCYC?

Do institutionals and insiders have more ownership in MRVI or BCYC?

Which has better valuation and earnings, MRVI or BCYC?

Do analysts rate MRVI or BCYC?

Is MRVI or BCYC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools